Prevent Cancer Foundation board member Monica Bertagnolli, M.D., FACS named next director of the National Cancer Institute
للنشر الفوري
كيرا مايستر
703-836-1746
kyra.meister@preventcancer.org
Monica Bertagnolli, M.D., FACS
الإسكندرية، فيرجينيا – The Biden administration has selected distinguished surgical oncologist and Prevent Cancer Foundation® board member Monica Bertagnolli, M.D., FACS, as the next director of the National Cancer Institute (NCI). Dr. Bertagnolli will replace the agency’s former director Ned Sharpless, who stepped down in April after a nearly five-year tenure. Dr. Bertagnolli is the first woman to be selected for this role, in which she will be responsible for the largest agency in the National Institutes of Health (NIH) focused on funding cancer research in the U.S.
Dr. Bertagnolli has served on the Foundation’s board since the beginning of 2022. As a relatively junior researcher, Dr. Bertagnolli received funding from the Prevent Cancer Foundation to support young researchers in her lab. She is also a member of the Foundation’s Medical Advisory Board. In this role, alongside other leaders in the fields of cancer prevention and early detection, Dr. Bertagnolli serves as a resource to continually update and review the information the Foundation uses to educate the public.
Currently, Dr. Bertagnolli is the Richard E. Wilson Professor of Surgery in the Field of Surgical Oncology at Harvard Medical School, and a member of the Gastrointestinal Cancer and Sarcoma Disease Centers at Dana-Farber Brigham Cancer Center, where she collaborates with colleagues in medical oncology, radiation oncology and pathology to treat cancer patients in a tertiary care setting.
Dr. Bertagnolli has a background in laboratory work focusing upon understanding the role of the inflammatory response in epithelial tumor formation. She previously led gastrointestinal correlative science initiatives within the NCI-funded Cancer Cooperative Groups and served as the Chief of the Division of Surgical Oncology at Dana-Farber Brigham Cancer Center. Dr. Bertagnolli has had numerous leadership roles in multi-institutional cancer clinical research consortia, currently serving as the group chair of the Alliance for Clinical Trials in Oncology, a nation-wide NCI-funded clinical trials group. She is also the chief executive officer of Alliance Foundation Trials, LLC, a not-for-profit corporation that conducts international cancer clinical trials.
“We are thrilled for Monica as she accepts this appointment, which recognizes her decades-long commitment to leadership and innovation in the field,” said Carolyn “Bo” Aldigé, Founder of the Prevent Cancer Foundation. “We have cherished Monica’s service on our board and longtime relationship with the Foundation over the years and look forward to her impending arrival in the greater Washington area as she brings her expertise in patient work and vast experience in clinical trials to the work of the National Cancer Institute.”
###
حول مؤسسة الوقاية من السرطان®
مؤسسة الوقاية من السرطان® هي المنظمة الأمريكية غير الربحية الوحيدة التي تركز فقط على إنقاذ حياة جميع السكان من خلال الوقاية من السرطان والكشف المبكر عنه. من خلال البحث والتعليم والتوعية والدعوة، ساعدنا عددًا لا يحصى من الأشخاص على تجنب تشخيص السرطان أو اكتشاف السرطان في وقت مبكر بما يكفي ليتم علاجه بنجاح.
تنهض المؤسسة لمواجهة التحدي المتمثل في تقليل وفيات السرطان بمقدار 40% بحلول عام 2035. ولتحقيق ذلك، نحن ملتزمون باستثمار $20 مليون في التقنيات المبتكرة للكشف عن السرطان مبكرًا وتعزيز فحص السرطان المتعدد، و$10 مليون لتوسيع نطاق فحص السرطان والتطعيم. الوصول إلى المجتمعات المحرومة طبيًا، و$10 مليون لتثقيف الجمهور حول خيارات الفحص والتطعيم.
لمزيد من المعلومات، يرجى زيارة الموقع www.preventcancer.org.